This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Canopy Growth Corporation (CGC) Dipped More Than Broader Market Today
by Zacks Equity Research
Canopy Growth Corporation (CGC) reachead $4.64 at the closing of the latest trading day, reflecting a -1.49% change compared to its last close.
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Canopy Growth Corporation (CGC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Canopy Growth (CGC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth (CGC) delivered earnings and revenue surprises of -19.35% and 6.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 125% and 12.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quipt Home Medical (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 66.67% and 3.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $7.60, making no change from the previous trading session.
Canopy Growth Corporation (CGC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Canopy Growth (CGC). This makes it worthwhile to examine what the stock has in store.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $7.30, moving +1.96% from the previous trading session.
Canopy Growth Corporation (CGC) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $7.13, moving -1.25% from the previous trading session.
Canopy Growth Corporation (CGC) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $6.50, denoting a +0.31% change from the preceding trading day.
Canopy Growth Corporation (CGC) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Canopy Growth Corporation (CGC) reachead $6.67 at the closing of the latest trading day, reflecting a +0.6% change compared to its last close.
Canopy Growth Corporation (CGC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth (CGC) delivered earnings and revenue surprises of 15.15% and 2.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
Canopy Growth Corporation (CGC) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $9.18, denoting a +0.77% change from the preceding trading day.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.69% and 1.80%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Canopy Growth Corporation (CGC) concluded the recent trading session at $10.85, signifying a -1.36% move from its prior day's close.